Phase I and pharmacokinetic studies of CYT6091, a novel ...
Purpose: A novel nanomedicine, CYT6091, constructed by simultaneously binding recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol to the surface of 27nm colloidal gold particles, was tested in a phase I dose escalation clinical trial in advanced stage cancer patients. Experimental design: CYT6091, whose dosing was based on the amount of rhTNF in the ...